Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | LIG1 | P18858 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 8/20 | 0.34 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.34 |
| ▸ | SLC6A5 | Q9Y345 | 3/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18746129 | 0.83 | MAPT (0.42) | KMT2ABACE1OPRM1 | |
| SCHEMBL5556903 | 0.75 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL5561878 | 0.75 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL1138347 | 0.75 | SLC6A9 (0.58) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL12410058 | 0.75 | SLC6A9 (0.40) | KMT2ASMN1; SMN2NPSR1SLC6A9OPRM1 | |
| Hydrochloric Acid SCHEMBL5562493 | 0.74 | SLC6A9 (0.57) | SLC6A9OPRM1SLC6A5KCNH2 | |
| SCHEMBL7354999 | 0.70 | KMT2A (0.51) | KMT2ASMN1; SMN2NPSR1TDP1LIG1 | |
| SCHEMBL12492338 | 0.70 | MEN1 (0.43) | KMT2A | |
| SCHEMBL3725717 | 0.69 | LIG1 (0.42) | TDP1LIG1SLC6A9OPRM1SLC6A5 | |
| Hydrochloric Acid SCHEMBL2336943 | 0.68 | LIG1 (0.41) | TDP1LIG1SLC6A9OPRM1SLC6A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | MCCORMICK KEVIN D | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166124-A1 | TRICYCLIC SPIROCYCLE DERIVATIVES AND METHODS OF USE | GPR119, TRPV1, NR3C2 | KMT2A 4310/4885SMN1; SMN2 3663/4885NPSR1 525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.